Greg Gin

Title(s)Assistant Health Sciences Professor, Urology
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Socioeconomic Barriers to Receiving Early Salvage Radiotherapy for Locally Advanced Prostate Adenocarcinoma: A Retrospective Single-Center Study. Cureus. 2024 Sep; 16(9):e68945. Heutlinger O, Azizi A, Harada G, Harris JP, Daneshvar M, Gin G, Uchio E, Mar N, Rezazadeh A, Seyedin SN. PMID: 39381448; PMCID: PMC11460723.
      View in: PubMed   Mentions:
    2. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis. Int Urol Nephrol. 2024 Feb; 56(2):539-546. Sultan MI, Huynh LM, Kamil S, Abdelaziz A, Hammad MA, Gin GE, Lee DI, Youssef RF. PMID: 37742327; PMCID: PMC10808487.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    3. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. Prostate Cancer Prostatic Dis. 2023 Aug 08. Javier-DesLoges J, Dall'Era MA, Brisbane W, Chamie K, Washington SL, Chandrasekar T, Marks LS, Nguyen H, Daneshvar M, Gin G, Kane CJ, Bagrodia A, Cooperberg MR. PMID: 37553435.
      View in: PubMed   Mentions:    Fields:    
    4. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. J Urol. 2023 07; 210(1):143-153. Bhojani N, Bidair M, Kramolowsky E, Desai M, Doumanian L, Zorn KC, Elterman D, Kaufman RP, Eure G, Badlani G, Plante M, Uchio E, Gin G, Paterson R, So A, Roehrborn C, Motola J, Kaplan S, Humphreys M. PMID: 37115632.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation. Biomolecules. 2023 03 13; 13(3). Xu X, Tian X, Song L, Xie J, Liao JC, Meeks JJ, Wu XR, Gin GE, Wang B, Uchio E, Zi X. PMID: 36979456; PMCID: PMC10046577.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    6. Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism. Molecules. 2023 Feb 09; 28(4). Liu Z, Song L, Xie J, Wu XR, Gin GE, Wang B, Uchio E, Zi X. PMID: 36838656; PMCID: PMC9966944.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    7. Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater Than 10 cm. J Endourol. 2021 12; 35(12):1785-1792. Grimaud LW, Chen FV, Chang J, Ziogas A, Sfakianos JP, Badani KK, Uchio EM, Anton-Culver H, Gin GE. PMID: 34148404.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022 Mar; 3(2):130-138. Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg SL, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Bhojani N. PMID: 35474721; PMCID: PMC8988689.
      View in: PubMed   Mentions: 9  
    9. Black race may be associated with worse overall survival in renal cell carcinoma patients. Urol Oncol. 2020 12; 38(12):938.e9-938.e17. Anastos H, Martini A, Waingankar N, Paulucci DJ, Beksac AT, Daza J, Patel HV, Gin GE, Sfakianos JP, Badani KK. PMID: 32950398.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 04; 27(2):10147-10153. Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys MR, Roehrborn CG, Kaplan S, Motola J, Zorn KC. PMID: 32333733.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    11. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology. 2019 Jul; 129:1-7. Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Kaplan S, Motola J, Desai M, Roehrborn C. PMID: 31059728.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    12. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. PMID: 30935383; PMCID: PMC6444674.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    13. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int. 2019 08; 124(2):321-328. Desai M, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Bhojani N. PMID: 30734990.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    14. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol. 2019 Feb; 37(2):116-122. Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE. PMID: 30509868.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    15. Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses. Ther Adv Urol. 2018 Dec; 10(12):383-391. Chong JT, Paulucci D, Lubin M, Beksac AT, Gin G, Sfakianos JP, Badani KK. PMID: 30574198; PMCID: PMC6295788.
      View in: PubMed   Mentions: 1  
    16. Risk factors and prognostic implications for pathologic upstaging to T3a after partial nephrectomy. Minerva Urol Nefrol. 2019 Aug; 71(4):395-405. Beksac AT, Paulucci DJ, Gul Z, Reddy BN, Kannappan M, Martini A, Sfakianos JP, Gin GE, Abaza R, Eun DD, Bhandari A, Hemal AK, Porter J, Badani KK. PMID: 30230296.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. WATER II (80-150 mL) procedural outcomes. BJU Int. 2019 01; 123(1):106-112. Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Zorn KC. PMID: 29694702.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    18. Trends in management of the small renal mass in renal transplant recipient candidates: A multi-institutional survey analysis. Urol Oncol. 2017 08; 35(8):529.e17-529.e22. Beksac AT, Paulucci DJ, Sfakianos JP, Reddy BN, Gin GE, Lerner SM, Badani KK. PMID: 28391999.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma. Urol Oncol. 2017 05; 35(5):192-200. Gin GE, Ruel NH, Kardos SV, Sfakianos JP, Uchio E, Lau CS, Yuh BE. PMID: 28041996.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    20. Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: A survey of U.S. transplantation centers. Urol Oncol. 2016 Feb; 34(2):57.e9-13. Gin GE, Pereira JF, Weinberg AD, Mehrazin R, Lerner SM, Sfakianos JP, Phillips CK. PMID: 26433443.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    21. Comparison of perioperative outcomes of retroperitoneal and transperitoneal minimally invasive partial nephrectomy after adjusting for tumor complexity. Urology. 2014 Dec; 84(6):1355-60. Gin GE, Maschino AC, Spaliviero M, Vertosick EA, Bernstein ML, Coleman JA. PMID: 25288573.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    Greg's Networks
    Concepts (105)
    Derived automatically from this person's publications.
    _
    Co-Authors (28)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _